EA201690456A1 - Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов - Google Patents

Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов

Info

Publication number
EA201690456A1
EA201690456A1 EA201690456A EA201690456A EA201690456A1 EA 201690456 A1 EA201690456 A1 EA 201690456A1 EA 201690456 A EA201690456 A EA 201690456A EA 201690456 A EA201690456 A EA 201690456A EA 201690456 A1 EA201690456 A1 EA 201690456A1
Authority
EA
Eurasian Patent Office
Prior art keywords
analogues
methods
methyl
bardoxolon
prevention
Prior art date
Application number
EA201690456A
Other languages
English (en)
Inventor
Мелани Пэй-Хэнг Чин
Колин Дж. Мейер
Original Assignee
Рита Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рита Фармасьютикалз, Инк. filed Critical Рита Фармасьютикалз, Инк.
Publication of EA201690456A1 publication Critical patent/EA201690456A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Настоящее изобретение относится к способам лечения и предотвращения эндотелиальной дисфункции и родственных нарушений, в том числе, например, легочной артериальной гипертензии, с применением бардоксолона метила или его аналогов.
EA201690456A 2013-08-23 2014-08-22 Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов EA201690456A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869527P 2013-08-23 2013-08-23
PCT/US2014/052382 WO2015027206A1 (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof

Publications (1)

Publication Number Publication Date
EA201690456A1 true EA201690456A1 (ru) 2016-06-30

Family

ID=51794949

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690456A EA201690456A1 (ru) 2013-08-23 2014-08-22 Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов

Country Status (19)

Country Link
US (3) US20150080465A1 (ru)
EP (1) EP3035937A1 (ru)
JP (3) JP6564372B2 (ru)
KR (1) KR102322057B1 (ru)
CN (2) CN112870202A (ru)
AU (2) AU2014308600B2 (ru)
BR (1) BR112016003454B1 (ru)
CA (1) CA2921386A1 (ru)
CL (1) CL2016000405A1 (ru)
EA (1) EA201690456A1 (ru)
HK (1) HK1223015A1 (ru)
IL (3) IL285832B2 (ru)
MX (2) MX2016002375A (ru)
MY (1) MY198522A (ru)
NZ (4) NZ744036A (ru)
PH (1) PH12016500358A1 (ru)
SG (2) SG10201906113RA (ru)
TW (2) TWI717026B (ru)
WO (1) WO2015027206A1 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356760B (es) 2008-01-11 2018-06-12 Dartmouth College Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
AU2009237579C1 (en) 2008-04-18 2016-05-12 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
EA025568B1 (ru) 2010-12-17 2017-01-30 Рита Фармасьютикалз, Инк. Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления
PE20150160A1 (es) 2012-04-27 2015-02-19 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimorficas y metodos de uso de los mismos
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
UY35023A (es) 2012-09-10 2014-03-31 Reata Pharmaceuticals Inc Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
EA201690456A1 (ru) * 2013-08-23 2016-06-30 Рита Фармасьютикалз, Инк. Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
KR20170117092A (ko) 2015-02-12 2017-10-20 리아타 파마슈티컬즈, 아이엔씨. 항산화 염증 조절제로서의 이미다졸릴 트리사이클릭 에논
CA2998681C (en) 2015-09-23 2024-02-06 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals Inc métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
CN106632574B (zh) * 2016-12-07 2018-05-29 广东天键生物科技有限公司 一种化合物、其制备方法及用途
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2018200692A1 (en) * 2017-04-26 2018-11-01 The Trustees Of The University Of Pennsylvania Methods and systems for virtual and augmented reality training for responding to emergency conditions
BR112021005919A2 (pt) * 2018-09-28 2021-07-27 Sichuan Haisco Pharmaceutical Co., Ltd. composto, composição farmacêutica e método para tratar uma doença em um mamífero
JPWO2020080482A1 (ja) * 2018-10-17 2021-09-09 Kagami株式会社 血液中のシスタチンｃ量に基づく腎機能検査結果の妥当性を検定する方法
CN114729001A (zh) * 2019-11-27 2022-07-08 鲁南制药集团股份有限公司 一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
WO2021202720A1 (en) * 2020-04-01 2021-10-07 Fronthera U.S. Pharmaceuticals Llc Use of triterpenoid nrf2 inhibitors
MX2022014034A (es) * 2020-05-09 2023-01-11 Reata Pharmaceuticals Holdings Llc Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
EP4259155A1 (en) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
US20220401396A1 (en) * 2021-06-22 2022-12-22 Asklepion Pharmaceuticals, Llc Action of l-citrulline to prevent or treat endothelial dysfunction
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
AU658374B2 (en) 1990-09-14 1995-04-13 Biosite Diagnostics Incorporated Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
WO1992018868A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
CA2412856A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
ZA200609228B (en) * 2004-04-23 2008-05-28 Celgene Corp Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
US20080280377A1 (en) 2007-05-08 2008-11-13 Abbott Laboratories Human b-type natriuretic peptide assay having reduced cross-reactivity with other peptide forms
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
MX356760B (es) * 2008-01-11 2018-06-12 Dartmouth College Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
AU2009237579C1 (en) 2008-04-18 2016-05-12 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
WO2009129548A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
PL3254675T3 (pl) 2009-02-13 2019-09-30 Reata Pharmaceuticals, Inc. Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me
PL2558105T3 (pl) * 2010-04-12 2020-04-30 Reata Pharmaceuticals, Inc. Metylowany bardoksolon do leczenia otyłości
EA201690456A1 (ru) * 2013-08-23 2016-06-30 Рита Фармасьютикалз, Инк. Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
MX2022014034A (es) * 2020-05-09 2023-01-11 Reata Pharmaceuticals Holdings Llc Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.

Also Published As

Publication number Publication date
JP2019048873A (ja) 2019-03-28
JP6701407B2 (ja) 2020-05-27
NZ630951A (en) 2018-09-28
TW202026003A (zh) 2020-07-16
TWI716341B (zh) 2021-01-21
MY198522A (en) 2023-09-04
CL2016000405A1 (es) 2017-02-24
AU2014308600B2 (en) 2020-03-05
IL285832B1 (en) 2023-09-01
AU2020203510A1 (en) 2020-06-18
BR112016003454B1 (pt) 2023-02-14
IL244171B (en) 2020-02-27
AU2020203510B2 (en) 2023-05-11
WO2015027206A8 (en) 2015-06-11
KR20160061994A (ko) 2016-06-01
IL272242B (en) 2021-09-30
IL272242A (en) 2020-02-27
TW201542211A (zh) 2015-11-16
CA2921386A1 (en) 2015-02-26
WO2015027206A1 (en) 2015-02-26
MX2016002375A (es) 2016-12-20
PH12016500358A1 (en) 2016-05-16
IL285832A (en) 2021-09-30
CN105517554B (zh) 2021-01-15
BR112016003454A2 (pt) 2017-08-01
SG11201601202WA (en) 2016-03-30
NZ744036A (en) 2020-09-25
NZ756256A (en) 2021-07-30
NZ774222A (en) 2023-01-27
IL244171A0 (en) 2016-04-21
CN105517554A (zh) 2016-04-20
SG10201906113RA (en) 2019-08-27
US20240115542A1 (en) 2024-04-11
IL285832B2 (en) 2024-01-01
HK1223015A1 (zh) 2017-07-21
EP3035937A1 (en) 2016-06-29
AU2014308600A1 (en) 2016-03-03
JP2016528300A (ja) 2016-09-15
TWI717026B (zh) 2021-01-21
CN112870202A (zh) 2021-06-01
US20150080465A1 (en) 2015-03-19
US20190091194A1 (en) 2019-03-28
KR102322057B1 (ko) 2021-11-05
MX2021002897A (es) 2021-06-08
JP2019131599A (ja) 2019-08-08
JP6526306B2 (ja) 2019-06-05
JP6564372B2 (ja) 2019-08-21

Similar Documents

Publication Publication Date Title
EA201690456A1 (ru) Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
EA201890908A1 (ru) Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201691582A1 (ru) Новые фармацевтические препараты
EA201791775A1 (ru) Цистеиновая протеаза
EA201890111A1 (ru) Замещенные производные оксопиридина
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201592157A1 (ru) Низкомолекулярные ингибиторы фиброза
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201690844A1 (ru) Ингибиторы gsk-3
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau